When Time Precludes Certainty: Intravenous Tenecteplase for Acute Global Aphasia in a Young Woman Along With Post-acute Diagnostic Reorientation
Abstract
Stroke mimics represent a major diagnostic challenge in the hyperacute setting. We report the case of a 29-year-old woman with no prior documented history of migraine or clinically significant headache who developed sudden-onset bradylalia and right hemisensory paresthesias, rapidly progressing to severe mixed aphasia with motor predominance, jargonaphasia, anomia, dysgraphia, alexia, and involuntary mixing of three languages. The initial National Institutes of Health Stroke Scale (NIHSS) score was five, accompanied by headache and vomiting. Intense agitation required procedural sedation for CT acquisition. Motion artifact rendered perfusion maps non-interpretable. Non-contrast CT showed no hemorrhage or established infarct (Alberta stroke programme early CT score (ASPECTS) 10), and CT angiography demonstrated no large vessel occlusion. Given the disabling neurological deficit and symptom onset within the therapeutic window, intravenous tenecteplase 17.5 mg was administered. Neurological recovery was complete within hours, and the delayed brain MRI was normal. Headache with Neurological Deficits and Cerebrospinal Fluid Lymphocytosis (HaNDL) syndrome remained an unconfirmed diagnostic consideration. Ultimately, the episode was assessed as a probable stroke mimic, most consistent with migraine with aphasic aura. This case illustrates that intravenous thrombolysis may be clinically justifiable under reasonable diagnostic uncertainty when the deficit is severe, the therapeutic…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.